No. 14 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark ...

After the slimming effect of Ozempic and Zepbound earned billions for Novo Nordisk and Eli Lilly, another class of ...

The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple ...

Trans-Tasman drug developer Aft Pharmaceuticals is targeting lucrative niche diseases its Big Pharma rivals have ignored ...

Zealand Pharma A/S ADR company and executive profile by Barron's. View the latest ZLDPY company infomation and executive bios.

Zealand Pharma Announces Financial Results for the First Three Months of 2025 Significant progress in the clinical pipeline, strengthening of organizational capabilities, and strategic partnership ...

Appointed Utpal Singh as Chief Scientific Officer in April 2025 to lead the next wave of differentiated and innovative medicines, building on Zealand Pharma’s strong peptide heritage and its ...

Appointed Utpal Singh as Chief Scientific Officer in April 2025 to lead the next wave of differentiated and innovative medicines, building on Zealand Pharma's strong peptide heritage and its ambition ...

COPENHAGEN, Denmark — The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma's "next generation" weight loss ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. The head of Zealand Pharma has called its $5.3bn partnership with Roche to commercialise an obesity drug ...

COPENHAGEN, April 24 (Reuters) - Danish biotechnology company Zealand Pharma (ZELA.CO), opens new tab said on Thursday it had enrolled the first patient in a mid-stage trial with its weight-loss ...